相似文献
1
Isoniazid hair concentrations in children with tuberculosis: a proof of concept study.
Int J Tuberc Lung Dis. 2016 Jun;20(6):844-7. doi: 10.5588/ijtld.15.0882.
2
Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis.
PLoS One. 2016 May 18;11(5):e0155887. doi: 10.1371/journal.pone.0155887. eCollection 2016.
3
Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis.
PLoS One. 2017 Dec 7;12(12):e0189101. doi: 10.1371/journal.pone.0189101. eCollection 2017.
4
Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting.
BMC Infect Dis. 2021 Jan 22;21(1):99. doi: 10.1186/s12879-020-05738-5.
5
Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India.
Int J Antimicrob Agents. 2018 May;51(5):663-669. doi: 10.1016/j.ijantimicag.2017.12.004. Epub 2017 Dec 11.
6
Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomes.
Int J Tuberc Lung Dis. 2021 Jan 1;25(1):52-60. doi: 10.5588/ijtld.20.0574.
7
Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
Int J Tuberc Lung Dis. 2013 Jun;17(6):800-6. doi: 10.5588/ijtld.12.0628.
8
Real-life isoniazid and rifampicin plasma concentrations in children: a tool for therapeutic drug monitoring of tuberculosis.
BMC Infect Dis. 2021 Oct 21;21(1):1087. doi: 10.1186/s12879-021-06764-7.
9
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Int J Tuberc Lung Dis. 2016 May;20(5):666-72. doi: 10.5588/ijtld.15.0288.
10
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Int J Tuberc Lung Dis. 2014 May;18(5):528-30. doi: 10.5588/ijtld.13.0730.
引用本文的文献
1
Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management.
J Pharm Anal. 2024 Jan;14(1):16-38. doi: 10.1016/j.jpha.2023.09.009. Epub 2023 Sep 22.
2
Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review.
Clin Pharmacokinet. 2023 Mar;62(3):375-398. doi: 10.1007/s40262-023-01220-y. Epub 2023 Mar 4.
3
Agreement Between Measures of Adherence to Isoniazid Preventive Therapy Among People With HIV in Uganda.
Open Forum Infect Dis. 2022 Oct 1;9(10):ofac516. doi: 10.1093/ofid/ofac516. eCollection 2022 Oct.
4
Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent infection in HIV-exposed uninfected children.
BMJ Open. 2020 Jan 21;10(1):e034308. doi: 10.1136/bmjopen-2019-034308.
5
Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis.
PLoS One. 2017 Dec 7;12(12):e0189101. doi: 10.1371/journal.pone.0189101. eCollection 2017.
本文引用的文献
1
Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children.
AIDS Res Hum Retroviruses. 2015 Oct;31(10):1009-14. doi: 10.1089/AID.2015.0111. Epub 2015 Aug 26.
2
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
PLoS One. 2015 Jun 8;10(6):e0129100. doi: 10.1371/journal.pone.0129100. eCollection 2015.
3
Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment.
Int J Infect Dis. 2015 Mar;32:101-4. doi: 10.1016/j.ijid.2014.12.001.
4
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.
Eur Respir J. 2015 Feb;45(2):571-4. doi: 10.1183/09031936.00157914.
5
Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya.
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):311-5. doi: 10.1097/QAI.0000000000000154.
6
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?
Eur Respir J. 2013 Dec;42(6):1449-53. doi: 10.1183/09031936.00073213.
7
Hair Analysis for Determination of Isoniazid Concentrations and Acetylator Phenotype during Antituberculous Treatment.
Tuberc Res Treat. 2012;2012:327027. doi: 10.1155/2012/327027. Epub 2012 Oct 2.
8
A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.
J Infect Dis. 2012 Nov;206(9):1453-61. doi: 10.1093/infdis/jis508. Epub 2012 Aug 20.
9
Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.
Clin Infect Dis. 2012 Jul;55(2):169-77. doi: 10.1093/cid/cis353. Epub 2012 Mar 30.
10
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy.
Clin Infect Dis. 2011 May;52(10):1267-75. doi: 10.1093/cid/cir131.
Zotero 插件